Bangkok: “Hong Thai” executives have clarified reports concerning an FDA finding of germs in an old batch of their inhalers, asserting compliance with standards and their readiness to assume full responsibility. Mr. Thiraphong Rabuetham, known as “Keng,” who owns Hong Thai Herbal Products Co., Ltd., spoke to Prachachat Business to address the Food and Drug Administration’s (FDA) findings that “Hong Thai Herbal Inhaler Formula 2” did not meet standards for microbial contamination.

According to Thai News Agency, Mr. Thiraphong explained that the company was alerted to the results and is actively seeking further details from the FDA to comprehend the type and severity of the microbes identified. This issue arose from a random inspection of an old lot from last year, number 332, dated December 2024, which revealed the presence of a virus exceeding standard levels. However, details regarding the impact on consumers remain unclear. The company is preparing to engage with the FDA to uncover the cause and devise a clear solution.

The owner assured that Hong Thai strictly follows production standards, with every batch undergoing a three-step culture test before release, ensuring compliance with criteria. No contamination has been found, and the company is prepared to take full responsibility if their product is found to be the source of any harm.

Mr. Thiraphong emphasized the company’s commitment to consumer safety, stating, “We prioritize customer safety and take full responsibility for any problems that arise. If consumers use any Hong Thai product and it is proven that the product has caused damage to the consumer, the company will take full responsibility.”